REVB · Revelation Biosciences, Inc. · Debt
$3.71
+0.02 (+0.54%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not anticipate that our current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that our unaudited financial statements for September 30, 2026 were issued, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$2.52M
Shares
683,442
Volume · Nov 20
1858
Avg daily vol (23 sessions)
20.32K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-09-30 | USD 344,588 | 10-Q filed 2026-11-05 |
| Noncurrent operating lease liabilities | 2026-09-30 | USD 460,811 | 10-Q filed 2026-11-05 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1810560
CUSIP
76135L887
13F (30d)
16 filings
14 filers
Visit website
Investor relations